Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Stock Has Average Target Price of $226.91 According to Analysts

Belite Bio logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts are broadly positive: Belite Bio has a “Moderate Buy” consensus, with 9 buys, 2 holds and 1 sell among 12 analysts. Their average 12-month price target is $226.91.
  • The company reported quarterly loss per share of $0.60, beating analysts’ estimate of a $0.79 loss. Shares opened at $162.56 and were down 1.1%.
  • Insiders have been selling: Company insiders sold 170,330 shares worth about $32.3 million over the past 90 days, including sales by the CEO and CFO.
  • Five stocks we like better than Belite Bio.

Shares of Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) have earned a consensus rating of "Moderate Buy" from the twelve research firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $226.91.

A number of research analysts have issued reports on BLTE shares. Cantor Fitzgerald raised their price target on shares of Belite Bio from $266.00 to $270.00 and gave the stock an "overweight" rating in a report on Wednesday, August 12th. UBS Group reissued a "buy" rating on shares of Belite Bio in a report on Thursday, September 3rd. Weiss Ratings reissued a "sell (d-)" rating on shares of Belite Bio in a report on Friday, October 2nd. HC Wainwright reissued a "buy" rating and issued a $245.00 target price on shares of Belite Bio in a research report on Thursday, October 15th. Finally, Morgan Stanley raised their target price on Belite Bio from $201.00 to $206.00 and gave the stock an "overweight" rating in a research note on Friday, August 14th.

Read Our Latest Report on Belite Bio

Belite Bio Stock Down 1.1%

BLTE opened at $162.56 on Tuesday. The company has a market cap of $6.55 billion, a P/E ratio of -59.55 and a beta of -1.19. The firm's 50-day moving average price is $160.26 and its 200-day moving average price is $160.22. Belite Bio has a 52-week low of $105.88 and a 52-week high of $200.00.

Belite Bio (NASDAQ:BLTE - Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.60) EPS for the quarter, topping analysts' consensus estimates of ($0.79) by $0.19. On average, research analysts anticipate that Belite Bio will post -3.08 EPS for the current fiscal year.

Insider Buying and Selling at Belite Bio

In other news, CFO Hao-Yuan Chuang sold 17,962 shares of the stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $196.42, for a total value of $3,528,096.04. Following the transaction, the chief financial officer directly owned 26,038 shares of the company's stock, valued at approximately $5,114,383.96. This represents a 40.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Yu-Hsin Lin sold 26,000 shares of the firm's stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $196.56, for a total value of $5,110,560.00. Following the completion of the transaction, the chief executive officer owned 70,134 shares of the company's stock, valued at approximately $13,785,539.04. The trade was a 27.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 170,330 shares of company stock worth $32,301,098. 13.29% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Belite Bio

A number of institutional investors have recently bought and sold shares of BLTE. Marshall Wace LLP purchased a new stake in shares of Belite Bio in the 3rd quarter valued at $15,282,000. Great Point Partners LLC purchased a new position in shares of Belite Bio during the third quarter worth $12,736,000. Affinity Asset Advisors LLC raised its holdings in shares of Belite Bio by 225.0% during the first quarter. Affinity Asset Advisors LLC now owns 65,000 shares of the company's stock worth $10,364,000 after purchasing an additional 45,000 shares during the last quarter. Candriam S.C.A. purchased a new position in shares of Belite Bio during the third quarter worth $10,711,000. Finally, Renaissance Technologies LLC acquired a new position in Belite Bio during the first quarter valued at $8,291,000. 0.53% of the stock is owned by hedge funds and other institutional investors.

About Belite Bio

(Get Free Report)

Belite Bio, Inc. is a clinical-stage biopharmaceutical company developing treatments for retinal and metabolic diseases. The company focuses on conditions with limited treatment options, including inherited retinal disorders and age-related eye disease. Its lead drug candidate, tinlarebant, is an oral therapy designed to reduce the accumulation of toxic vitamin A byproducts in the retina. Belite Bio is evaluating tinlarebant for Stargardt disease and geographic atrophy associated with dry age-related macular degeneration.

See Also

Analyst Recommendations for Belite Bio (NASDAQ:BLTE)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Belite Bio Right Now?

Before you consider Belite Bio, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Belite Bio wasn't on the list.

While Belite Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines